– Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors – – Appointment of Mark Kirschbaum , M.D. as Chief Medical Officer – – $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures – BERKELEY HEIGHTS, N.J. , Jan.
BERKELEY HEIGHTS, N.J. , Dec. 30, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech
- Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors - BERKELEY HEIGHTS, N.J. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc.
Former CMO & Head of R&D of ArQule joins the Board BERKELEY HEIGHTS, N.J. , Dec. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today
- Conference Call Scheduled November 11, 2020 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell
BERKELEY HEIGHTS, N.J. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results
A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib BERKELEY HEIGHTS, N.J. , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a
BERKELEY HEIGHTS, N.J. , Oct. 23, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum , M.D.
BERKELEY HEIGHTS, N.J. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals , Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company is scheduled to participate in a
BERKELEY HEIGHTS, N.J. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ( Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that an abstract highlighting clinical data with
- Conference Call Scheduled August 12, 2020 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J. , Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell
BERKELEY HEIGHTS, N.J. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results on
-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – -- Data builds on growing body of evidence indicating the promise of dual CDK2/9 inhibition -- BERKELEY
- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - - Following Recent Financing Cash Runway to End of 2022 - BERKELEY HEIGHTS, N.J. , May 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company
BERKELEY HEIGHTS, N.J. , May 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2020 financial results on
BERKELEY HEIGHTS, N.J. , April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced
BERKELEY HEIGHTS, N.J. , April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of a public offering with
-Evaluation of Fadraciclib and Seliciclib to Promote Apoptosis of Inflammatory Neutrophils in the Setting of COVID-19 Lung Injury- BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom , April 20, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the
BERKELEY HEIGHTS, N.J. , April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that effective at 5:00 p.m., Eastern Time
– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib -venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – – Conference Call Scheduled February 26, 2020 at 4:30 p.m. EDT – BERKELEY HEIGHTS, N.J. , Feb.